Advances in RSV Vaccine Research and Development
Respiratory syncytial virus (RSV) remains a leading cause of acute lower‑respiratory infections, accounting for roughly 33 million cases and over 3 million hospitalizations each year, especially in children under five and older adults. Recent advances focus on stabilizing the prefusion F (preF) antigen, enabling a wave of next‑generation vaccines and monoclonal antibodies across pediatric, maternal, and elderly populations. Companies such as Clover Biopharmaceuticals and Moderna have entered late‑stage trials with protein‑subunit and mRNA combination candidates that also target hMPV. Real‑world effectiveness studies in England report more than 80 % protection against RSV‑related hospital admission and severe disease in adults over 75.
Merck, Amgen Double Down on Bad Cholesterol to Vanquish Number 1 Killer
Merck’s oral PCSK9 inhibitor enlicitide cut LDL‑C by 64.6% in an eight‑week Phase III trial, outperforming other oral non‑statin drugs. Updated ACC/AHA lipid guidelines now require LDL‑C < 55 mg/dL for ASCVD patients, leaving roughly 70% of statin users above target. The tighter goals...
Published FDA Rejections Point to Manufacturing, Data Gaps as Key Stumbling Blocks
The FDA’s new policy to publish complete response letters (CRLs) has made over 350 rejection letters publicly available, revealing that more than half of drug rejections stem from manufacturing problems and 41% from product‑quality issues. Analysts say the transparency lets...
Trump Signs Off on Plan to Oust Embattled FDA Commissioner Marty Makary: Report
President Donald Trump has reportedly signed off on a plan to remove FDA Commissioner Marty Makary, whose brief tenure has been marked by a series of unexpected drug rejections, internal leadership churn, and a contentious national priority voucher program. Makary...
Gilead Sets Blockbuster Bar for Yeztugo’s First Full Year on the Market
Gilead announced a $1 billion sales target for its twice‑yearly PrEP injection Yeztugo in 2026, up from a prior $800 million outlook. The drug generated $166 million in Q1, a 72% increase from the previous quarter, and 95% of U.S. patients enjoy $0...
Ascendis Retreats to Rare Endocrinology Wheelhouse as Cancer Plans Falter
Ascendis Pharma announced it will halt development of onvapegleukin alfa, its IL‑2 β/γ oncology candidate, after a Phase 1/2 trial showed modest survival benefit in platinum‑resistant ovarian cancer. The company cited a strategic mismatch and will instead concentrate on its rare‑endocrinology franchise,...
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
Atara Biotherapeutics and Pierre Fabre’s EBV‑positive PTLD cell therapy Ebvallo received a regulatory U‑turn after FDA CBER director Vinay Prasad stepped down. The agency now says a single‑arm study with an appropriate historical control can satisfy the “adequate and well‑controlled” requirement, allowing...
Gilead Wipes Out Most of Arcellx Workforce
Gilead Sciences completed its $7.8 billion acquisition of Arcellx and immediately announced the layoff of 192 employees, wiping out roughly 87 % of the biotech’s workforce. The cuts split between 108 jobs in Redwood City, California and 84 in Rockville, Maryland, with...
Entrada Crashes as Duchenne Therapy Comes in ‘Below Expectations’ in Early Study
Entrada Therapeutics reported that its investigational oligonucleotide ENTR‑601‑44 raised dystrophin levels by 2.36% in the first cohort of its Phase 1/2 ELEVATE‑44‑201 trial, far below the company’s double‑digit target. The modest protein increase triggered a 50% plunge in the Boston‑based biotech’s...
Sarepta Says to ‘Exercise Prudence’ in Setting Expectations for Elevidys’ Recovery
Sarepta Therapeutics urged analysts to "exercise prudence" as it navigates a turbulent recovery after three patient deaths linked to its Duchenne muscular dystrophy gene therapy Elevidys. The FDA imposed a boxed warning and limited the drug to ambulatory patients aged...
Fibrosis, IPF and the Search for Better Therapies
The BioSpace "Denatured" podcast episode spotlights the persistent challenges of idiopathic pulmonary fibrosis (IPF) and broader fibrotic diseases. Host Jennifer C. Smith‑Parker interviews Georg Vo Beiske, CEO of Tribune Therapeutics, and Jonas Hallén, CMO of Calluna Pharma, to dissect current treatment gaps and...
Increased Capital Boosts Biotech R&D Job Postings, Employment
Biotech R&D job postings on BioSpace jumped 21% year‑over‑year in April, marking the longest month‑over‑month rise since mid‑2024. A CBRE report shows biotech employment reached a record 295,600 in February after five consecutive months of growth, the longest streak since...
Pfizer, Lilly, More Report Q1, FDA Names Acting CBER Director and an ALS Awakening
Pfizer posted first‑quarter earnings that topped consensus estimates, yet analysts deemed the beat insufficient given higher expectations for the New York‑based giant. Eli Lilly delivered a striking 56% revenue surge, though the company noted that price reductions on several products capped its...
Founders Face Pressure From All Sides as Biotech Crawls Toward Recovery
Biotech founders are confronting a tighter capital environment as investors gravitate toward AI and high‑interest‑rate caution, according to a BioSpace gathering in Salt Lake City. The slowdown follows the 2019‑21 boom, leaving early‑stage companies to rely on accelerators like Altitude...
Pfizer Is a 2029 Story but Q126 Lays Foundation for Growth
Pfizer reported first‑quarter revenue of $14.5 billion, up 2%, and highlighted a legal settlement that pushes generic entry for its $6 billion ATTR‑CM drug Vyndamax to 2031, extending its exclusivity. The settlement also adds $7 billion to Pfizer’s acquisition budget, supporting its plan...
BioNTech Moves to Close Multiple Manufacturing Plants, Affecting 1,860 Jobs
BioNTech announced it will shut down three German manufacturing sites—Idar‑Oberstein, Marburg and Tübingen—and its Singapore plant by the end of next year, affecting about 1,860 employees. The closures are part of a network consolidation aimed at eliminating idle capacity as...
Sertraline Manufacturer Recalls Antidepressant Batch After UK Packaging Mix-Up
Amarox, a subsidiary of India’s Hetero Group, is recalling a batch of 100 mg sertraline tablets after a packaging error placed citalopram strips in the same cartons. The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued the recall following a...
Sarepta, Amylyx and Neumora Look Ahead to Key Catalysts as Q1 Earnings Roll In
Sarepta Therapeutics, Amylyx, and Neumora Therapeutics are set to report Q1 results amid pivotal milestones. Sarepta faces scrutiny after two DMD patient deaths and awaits FDA review of Amondys 45 and Vyondys 53, plus a sirolimus safety study. Amylyx, after pulling its...
Passage Cuts 75% of Workforce After FDA Trial Design Request
Passage Bio announced it will cut roughly 75% of its workforce—about 18 of 24 employees—after the FDA rejected its proposed single‑arm registrational trial for PBFT02, a gene therapy targeting frontotemporal dementia with granulin mutations. The company expects to incur $3.3 million...
Gene Therapy’s Evidence Problem—Lessons From Recent FDA Decisions
The FDA recently rejected REGENXBIO’s gene‑therapy candidate RGX‑121, citing an unvalidated biomarker as the primary endpoint and reliance on an external natural‑history control. The decision highlights a broader pattern of mixed regulatory outcomes for advanced therapeutics, with approvals like Sarepta’s...
PCI Adds US Sterile Fill/Finish Capabilities Through $1B Global Expansion Drive
PCI Pharma Services announced a $1 billion global expansion, allocating $100 million to upgrade its San Diego campus with a high‑speed isolator line that will more than double its prefilled syringe capacity. The company also launched a GMP‑ready isolator vial and lyophilization line...
First FDA ODAC Meeting without Pazdur Highlights Conceptual Challenges with Trial
The FDA’s Oncology Drugs Advisory Committee (ODAC) convened for the first time in nine months to review two AstraZeneca cancer therapies. The panel voted 6‑3 against approving camizestrant, an oral SERD for HER2‑negative advanced breast cancer, citing the trial’s failure...
Summit Shares Descend as PD-1/VEGF Asset Misses Early Survival Mark
Summit Therapeutics announced that its anti‑PD‑1/VEGF bispecific, ivonescimab, failed to meet the interim progression‑free survival threshold in the Phase 3 HARMONi‑3 trial for squamous NSCLC. The miss triggered a 26% plunge in Summit’s share price, closing at $16.12. An independent data...
UCB Captures Candid in $2.2B Autoimmune Deal as Pharma’s M&A Train Chugs Along
UCB announced a $2 billion acquisition of Candid Therapeutics, adding a pipeline of T‑cell engager drugs aimed at autoimmune and inflammatory diseases. The deal also includes up to $200 million in milestone payments and is expected to close by Q3 2026. Candid’s...
Obesity Ends Oncology’s Long Reign as Top Contributor to Biopharma Pipeline Value
Deloitte’s 2025 pipeline analysis shows obesity overtaking oncology as the top value‑generating therapeutic area, accounting for 25% of total pipeline worth. Eli Lilly and Novo Nordisk dominate the obesity segment, together holding roughly 96% of its assigned value. GLP‑1/GIP agonists are driving...
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
May’s FDA docket is light, but the decisions on four high‑profile drugs could reshape market dynamics. Argenx is seeking to broaden Vyvgart’s label to seronegative myasthenia gravis patients, potentially adding 11,000 new users. AstraZeneca and Daiichi Sankyo aim to secure...
Moderna Beats Revenue Expectations with $389M, but Litigation Dogs Earnings
Moderna reported first‑quarter revenue of $389 million, roughly 50% above analysts’ expectations, while vaccine sales reached $352 million, beating consensus. A $950 million upfront settlement with Arbutus over lipid‑nanoparticle patents pushed the net loss to $1.3 billion, though it was still better than the...
Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug
Amgen is positioning its bispecific antibody‑peptide MariTide as the premier monthly or less‑frequent obesity treatment. The company launched a Phase 3 MARITIME‑Switch study to evaluate switching patients from weekly GLP‑1 injections to four‑to‑six monthly doses. Phase 2 data showed up to a...
AstraZeneca’s Breast Cancer Drug Fails to Earn Backing of FDA Advisory Committee
The FDA’s advisory committee voted against recommending AstraZeneca’s oral SERD camizestrant for HR⁺/HER2‑ metastatic breast cancer patients with an ESR1 mutation, citing concerns over the Phase 3 SERENA‑6 trial design. The study switched patients to camizestrant at the point of mutation...
Corcept Ties ALS Drug to Improved 2-Year Survival as Phase 3 Start Date Nears
Corcept Therapeutics reported that its experimental ALS drug dazucorilant reduced the two‑year risk of death by roughly 87% in a Phase 2 extension study, despite missing its primary motor‑function endpoint. The survival benefit was most pronounced at the 300 mg dose, though...
FDA Taps Szarama as Acting CBER Director as Prasad’s Tumultuous Tenure Ends
Vinay Prasad is leaving his role as head of the FDA’s Center for Biologics Evaluation and Research (CBER) after a contentious tenure that included the Elevidys gene‑therapy shutdown and multiple rare‑disease therapy rejections. The agency has named his deputy, biophysicist Katherine Szarama,...
Tackling Drug Resistance Must Become Biotech’s Next Frontier
Drug resistance underlies roughly 90% of the 600,000 cancer deaths in the United States each year, limiting the durability of modern therapies. Kairos Pharma, founded in 2013, is focusing on the biology of resistance with its candidate ENV‑105, which aims...
AbbVie Tops Q1 Estimates, Raises Outlook and Discontinues Cancer Candidate
AbbVie reported $15 billion in first‑quarter revenue, a 12.4% year‑over‑year increase, driven by strong immunology and a 26% surge in neuroscience sales. Immunology products Skyrizi and Rinvoq generated $7.29 billion, while the migraine drug Qulipta boosted neuroscience revenue to $2.87 billion. The company...
With Growth Curve Trending up, Biogen Looks to Early-Stage Assets for ‘Next Generation’
Biogen, fresh from its $5.6 billion acquisition of Apellis, announced on its Q1 earnings call that it will pivot toward early‑stage assets to thicken a pipeline it described as “quite thin.” The shift comes as Alzheimer’s patients transition off Eli Lilly’s Kisunla,...
Biogen Ready to Catch Alzheimer’s Patients Transitioning Off Lilly’s Kisunla
Biogen is positioning its Leqembi therapy to capture Alzheimer’s patients who will finish Eli Lilly’s 18‑month Kisunla regimen and need a maintenance option. Leqembi, approved in January 2023, saw a 74% year‑over‑year sales jump to $168 million in Q1 2026, beating expectations. Biogen is...
AstraZeneca Bullish on $80B Sales Goal After Beating Expectations, Phase 3 Data Wins
AstraZeneca reported first‑quarter sales of $15.3 billion, surpassing the $14.7 billion consensus estimate and delivering 8% constant‑currency growth. The surge was led by oncology products Enhertu and Imfinzi, while the rare‑disease unit contributed $2.4 billion, anchored by Ultomiris. New alliance revenue from the...
GSK’s Shingrix Strategy Shift Drives Sales Beat Even as Vaccines Slow
GSK’s shingles vaccine Shingrix posted a 20% sales jump to $1.4 billion in Q1 2025, beating analysts’ $1.15 billion forecast. The boost came largely from a 51% year‑on‑year surge in Europe and a 12% rise in the United States after the company...
AbbVie Sinks Talons Into KRAS with Right to Buy Kestrel for up to $1.45B
AbbVie has secured an exclusive option to acquire Kestrel Therapeutics for up to $1.45 billion, contingent on milestone achievements. Kestrel has just begun dosing its oral pan‑KRAS inhibitor KST‑6051 in a Phase 1 trial targeting solid tumors driven by KRAS mutations. The...
Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3
Boehringer Ingelheim and Zealand Pharma reported that their glucagon/GLP‑1 dual agonist survodutide achieved a 13.4% (39.2 lb) average weight loss after 76 weeks in the Phase 3 SYNCHRONIZE‑1 trial, meeting primary endpoints and reducing waist circumference. Analysts compared the outcome to Novo...
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Combination regimens dominated AACR 2026, with biotech firms showcasing new cocktail data across multiple tumor types. Marengo Therapeutics reported that its dual‑T‑cell agonist invikafusp alfa combined with Gilead’s ADC Trodelvy produced complete or partial responses in 40% of heavily pretreated...
Novartis’ Sales Dip as Generics Pressure Intensifies, Radioequivalents Loom
Novartias first‑quarter net sales slipped 5% to $13.11 billion, primarily due to U.S. generic erosion of its heart‑failure drug Entresto. While earnings per share fell 11% to $1.65, growth was buoyed by double‑digit gains in Kisqali, Kesimpta and the radiopharma Pluvicto....
Big Pharma–Backed Coultreon Bags $125M Series A to Unlock Alternative Immune Pathway
Coultreon Biopharma announced a $125 million Series A round led by Sofinnova Investments, with participation from Novo Holdings, Forbion, Regeneron Ventures and others. The capital will fund COL‑5671, an oral SIK3 inhibitor, into Phase 2 trials for psoriasis and ulcerative colitis. The drug...
Revolution Levels Legal Threat on Erasca as Pancreatic Cancer Rivalry Heats Up
Revolution Medicines, after its Phase 3 pancreatic cancer drug daroxinrasib showed a median overall survival of 13.2 months and lifted its share price, sent a cease‑and‑desist letter to rival Erasca demanding the U.S. halt of ERAS‑0015, alleging patent infringement and misleading...
Compass Shares Crash as ‘Confounding’ Survival Data Raise Approvability Questions for Bispecific
Compass Therapeutics reported that its bispecific antibody tovecimig failed to meet the secondary overall survival (OS) endpoint in the Phase 2/3 COMPANION‑002 trial, though it achieved a 56% reduction in progression risk, extending progression‑free survival (PFS) to 4.7 months versus 2.6...
Turn Health Data Into Impact: Browns University's Online Master in Biostatistics & Health Data Science
Brown University has launched an online Master’s in Biostatistics with a concentration in Health Data Science, delivered through its School of Public Health and School of Professional Studies. The 20‑month, five‑semester program comprises nine courses and a capstone project that...
Daiichi Sankyo Shares Slip After Delaying Annual Earnings Report
Daiichi Sankyo postponed its FY2025 earnings release from April 27 to May 11, 2026, citing the need to finalize financials and review supply plans amid shifting business conditions. The delay coincides with an accelerated rollout of its five‑year strategic plan, now set...
Pfizer Culls Early PD-L1 Asset After Series of Clinical Wins, Deals in Cancer
Pfizer terminated the Phase 1 study of its early‑stage PD‑L1 antibody‑drug conjugate PF‑08046037 after enrolling eight patients, citing strategic business reasons rather than safety or efficacy concerns. At the same time, the company announced a 47% reduction in disease‑progression risk for...
Opinion: Prasad’s FDA Exit Good for Rare Diseases but New CBER Head Must Repair Eroded Trust
Vinay Prasad’s exit from the FDA’s Center for Biologics Evaluation and Research (CBER) follows a Senate hearing that highlighted inconsistent approval pathways for rare‑disease therapies. Industry sponsors and patient advocates complained that the agency reversed previously negotiated trial designs, leaving patients...
FDA Approval of Regeneron’s Hearing Loss Gene Therapy Breaks Barriers
Regeneron Pharmaceuticals received FDA approval for Otarmeni, the first gene therapy targeting congenital deafness caused by otoferlin deficiency. The treatment, approved under the Commissioner’s National Priority Voucher program, demonstrated clinically meaningful hearing gains in 11 of 12 patients in the...
BBOT Shakes up Leadership as RAS Competitors Get More Visibility
BridgeBio Oncology Therapeutics (BBOT) dismissed CEO Eli Wallace and promoted CSO Pedro Beltrán to chief executive as the board seeks faster progress on its RAS‑focused pipeline. Shares, already down 18% to $8.76, slipped further after the announcement. The board also...